Therapeutic focus

Liver

Liver insufficiency is a condition where the liver is unable to perform its normal functions due to damage or disease.

Hepatic cirrhosis is a common (more than 200,000 new cases per year in the US) degenerative disease of the liver resulting in scarring and liver failure, leading to death with no known cure to date.

Major problems of hepatocyte transplantation, the current most viable treatment option, is insufficient amount of hepatocyte donors and not standardized hepatocyte isolation technique.

Immorta Bio developed unique technology providing practically unlimited hepatocyte progenitors through the PPC platform, as well as standardized intrahepatic injection techniques. Our hepatic progenitor cells act to inhibit and reverse chronic liver disease and stimulate recovery and regeneration of the liver.

Heart

Heart failure is usually defined as a clinical condition characterized by the inability of the heart to sufficiently pump blood to meet the body’s needs.

The American Heart Association states that approximately 6 million Americans have been diagnosed with heart failure, and an additional 670,000 new cases are diagnosed annually.

There is no cure for heart failure, and existing medications do not address the underlying issue: death of cardiomyocytes.

The Company’s approach to heart failure is creating patient-specific cardiac cells which can be administered and take over the function of dead or dying cardiomyocytes.

Arteries

Critical limb ischemia (CLI) is an advanced form of peripheral artery disease that is a debilitating condition caused by occlusion of the arteries supplying blood to the legs. Approximately 20-45% of patients require amputation. For these patients, the 1-year mortality rate is estimated to be as high as 45%.

Treatment for CLI is focused on revascularization using surgical or endovascular means. Unfortunately, less than half of the patients undergo these procedures, and efficacy is limited due to high levels of restenosis and the need for further surgery.

Angiogenesis, the process of making new blood vessels in tissues lacking oxygen, is an attempt by the body to correct the lack of circulation in the legs of patients with critical limb ischemia.

Evidence suggests that administration of cells which produce cytokines provides significant therapeutic effects.

Join our newsletter to stay up to date on features and releases

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

By subscribing, you are acknowledging your consent to receive Immorta Bio newsletters

19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180

305 632-2939

info@immortabio.com